Drs. David Ilson, Sumanta (Monty) Pal, and Tian Zhang discuss new research presented at the 2022 ESMO Congress, including studies about treating liver, colorectal, stomach, kidney, bladder, and prostate cancers.
Radiation oncologist and cancer survivor Dr. Arthur Hamberger shares how being diagnosed with cancer led him to a career in oncology, what it was like being diagnosed with multiple cancers 45 years later, and his advice on coping with a cancer diagnosis.
In this webinar, experts discuss new research in bladder cancer, kidney cancer, prostate cancer, and testicular cancer presented at the 2022 ASCO Annual Meeting and the 2022 Genitourinary Cancers Symposium.
In this webinar, experts discuss new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting and the 2021 Genitourinary Cancers Symposium that highlighted advances in treating prostate, bladder, kidney, and testicular cancers.
In the latest podcast in the “Clinical Trials in Genitourinary Cancers” series, experts discuss 3 clinical trials testing new treatment options for kidney cancer, muscle-invasive bladder cancer, and metastatic castration-sensitive prostate cancer.
Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer: Research From the 2021 Genitourinary Cancers Symposium
Learn more about research presented at the 2021 Genitourinary Cancers Symposium, including immunotherapy for people with high-risk bladder cancer and a link between less PSA screening and diagnoses of metastatic prostate cancer.
In the latest podcast in the “Clinical Trials in Genitourinary Cancers” series, experts discuss 3 clinical trials testing new treatments for prostate, bladder, and kidney cancers.
Dr. Neeraj Agarwal discusses 3 clinical trials presented at the 2020 ESMO Virtual Congress that studied new treatments for advanced kidney cancer, prostate cancer, and bladder cancer.
In the latest podcast in the “Clinical Trials in Genitourinary Cancers” series, experts discuss 3 clinical trials testing potential new treatments for prostate, bladder, and kidney cancers.
ASCO20 Virtual Scientific Program: Immunotherapy for Colorectal Cancer, Maintenance Therapy for Bladder Cancer, Precision Medicine in Childhood Cancers, Treatment for Gestational Trophoblastic Disease, and Targeted Therapy for Non-Small Cell Lung Cancer
Read research highlights just released from the ASCO20 Virtual Scientific Program. They include studies on immunotherapy for metastatic colorectal cancer and gestational trophoblastic disease, maintenance therapy for advanced bladder cancer, the potential of precision medicine for childhood cancers, and targeted therapy after surgery for EGFR-positive non-small cell lung cancer.